Acarix: Redeye Resumes Research Coverage

We resume our coverage of Acarix after the recent capital raise, where Redeye acted as a financial advisor. The interest to participate in the transactions was high and the rights issue was subscribed to about 123%, meaning guarantee undertakings will not be utilized. Factoring in the cash and the new number of shares, we present a new fair value range. Our new Base case is SEK 1.0 (1.5) per share..